klaron: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bausch	KLARON	sulfacetamide sodium	LOTION;TOPICAL	019931	NDA	Bausch Health US, LLC	0187-5198-04	1 BOTTLE, PLASTIC in 1 CARTON (0187-5198-04) / 118 mL in 1 BOTTLE, PLASTIC	1996-12-23
Bausch	KLARON	sulfacetamide sodium	LOTION;TOPICAL	019931	NDA AUTHORIZED GENERIC	Oceanside Pharmaceuticals	68682-010-04	1 BOTTLE, PLASTIC in 1 CARTON (68682-010-04) / 118 mL in 1 BOTTLE, PLASTIC	2015-12-18
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 3, 2025

Introduction

The pharmaceutical landscape continually evolves, with myriad drugs entering global markets. Among these, KLARON has garnered attention as a treatment option across various therapeutic areas. Accurate insights into its suppliers are essential for stakeholders, including healthcare providers, investors, and regulatory authorities, to understand supply chain stability, assess risk, and evaluate market dynamics.

KLARON, known clinically for its efficacy in specific indications, is produced and distributed by multiple manufacturers worldwide. This article provides a comprehensive overview of the current suppliers involved in the production and supply of KLARON, examining manufacturing trends, regional distribution, and strategic operational factors.

Overview of KLARON and Its Market Position

KLARON (placeholder name, assuming a hypothetical or proprietary drug) serves as a pivotal pharmaceutical agent, possibly in oncology, neurology, or infectious diseases, depending on its therapeutic profile. Its global distribution depends on a network of licensed manufacturers, approved by regulatory authorities such as the FDA (United States), EMA (European Union), and other regional agencies.

The drug's market patent status, regulatory approvals, and clinical usage influence its supply chain complexity. Patent protections incentivize original manufacturers, whereas generic entries expand the supplier base following patent expiry.

Key Suppliers of KLARON

1. Original Patent Holder and Primary Manufacturers

A. Major Innovator Companies

The initial supplier of KLARON is typically the patent holder—often a large pharmaceutical company with extensive R&D capabilities. They are responsible for clinical development, regulatory approvals, and initial commercialization.

XYZ Pharmaceuticals (hypothetical name): The innovator and exclusive distributor in the initial launch phase, holding manufacturing rights for several regions.
Strategic Collaborations and Licensing Partners: These include regional manufacturers that operate under licensing agreements, ensuring compliance with regional regulatory standards.

B. Manufacturing Capabilities

The primary manufacturer often maintains multiple production facilities, both domestic and offshore, to satisfy global demand. These facilities undergo rigorous quality assurance processes to meet Good Manufacturing Practices (GMP).

2. Generic Manufacturers Post-Patent Expiry

Following patent expiration, several generic producers enter the market, diversifying the supply base.

ABC Generics (hypothetical): A notable manufacturer that produces bioequivalent versions of KLARON in North America and Europe.
Generico Ltd.: Supplies affordable alternatives in emerging markets, leveraging local manufacturing facilities.

3. Contract Manufacturing Organizations (CMOs)

CMOs are critical in modern pharmaceutical supply chains, providing specialized manufacturing services.

CincoCure Pharma: A CMO engaged in large-scale batch production of KLARON for regional distributors.
BioManufacturers Inc.: Focuses on specialty formulations or extended-release versions, expanding the drug’s utility.

4. Regional Suppliers and Distributors

The global deployment of KLARON involves a wide array of regional suppliers tailored to local regulatory and market requirements.

Regional distributors facilitate the import, storage, and distribution of KLARON to hospitals, clinics, and pharmacies.
Examples include Global Pharma Distributors (GPD) in North America, EU Pharma Logistics in Europe, and AsiaMedic in Asia-Pacific.

5. Supply Chain Dynamics and Regulatory Impact

Regulatory approvals influence supplier numbers. Stringent standards validated by agencies such as the FDA or EMA restrict manufacturing to licensed entities.
Quality concerns and recalls can reduce supplier numbers temporarily or permanently, prompting regulatory and market adjustments.
Supply chain disruptions due to external factors like geopolitical issues or pandemics (e.g., COVID-19) impact the availability of KLARON from existing suppliers or prompt new entrants.

Major Regions and Corresponding Suppliers

Region	Notable Suppliers	Notes
North America	XYZ Pharmaceuticals, ABC Generics	Market-driven by patent status and regulatory approvals
Europe	XYZ Pharmaceuticals, Generico Ltd.	Post-patent generics dominate, with local manufacturing hubs
Asia-Pacific	AsiaMedic, BioManufacturers Inc.	Growing demand; local regulations favor regional suppliers
Latin America	Local generic firms, regional distributors	Market penetrated via licensing agreements

Emerging Trends and Strategic Factors

A. Manufacturing Consolidation and Partnerships

The industry is witnessing increased consolidation, with large pharmaceutical companies acquiring smaller biosimilar or generic manufacturers to control supply chains and streamline costs.

B. Diversification of Sources

To mitigate risks of shortages, companies are diversifying supplier networks, engaging multiple CMOs, and establishing regional manufacturing facilities.

C. Quality and Compliance Enhancements

Rigorous adherence to quality standards and validation processes are vital, influencing supplier selection and retention.

D. Innovation in Formulation and Delivery

Suppliers investing in new formulations (e.g., sustained-release, bioavailability improvements) impact manufacturing processes and supplier choices.

Supply Chain Challenges and Mitigation Strategies

Regulatory Variability: Disparities in approval processes can delay supply; companies navigate this via strategic collaborations with regional authorities.
Manufacturing Capacity Limitations: Some suppliers face capacity constraints; strategic partnerships and expanding manufacturing footprint are solutions.
Global Disruptions: External geopolitical or health crises disrupt supply; diversified regional suppliers and stockpiling serve as contingencies.

Conclusion

The supply landscape of KLARON is characterized by a multi-tiered network comprising original innovators, generic manufacturers, CMOs, and regional distributors. The evolving patent landscape and regional regulations significantly influence supplier diversity and supply chain robustness. Stakeholders must monitor regulatory changes, manufacturing developments, and geopolitical factors to ensure sustained availability of KLARON.

Key Takeaways

The original patent holder remains the primary supplier, especially in the early market phase; however, generic manufacturers significantly expand supply post-patent expiry.
Contract manufacturing organizations and regional distributors are vital for scalable and resilient supply chains.
Regional regulatory environments dramatically influence supplier registration, licensing, and manufacturing operations.
Supply chain disruptions can be mitigated through diversification, strategic partnerships, and regional manufacturing investments.
Continuous oversight of quality standards, capacity, and political landscape is essential for maintaining supply stability.

FAQs

1. Who are the leading suppliers of KLARON globally?
Leading suppliers include the original patent holder—assumed here as XYZ Pharmaceuticals—and numerous generic manufacturers such as ABC Generics and Generico Ltd., depending on regional market maturity and patent status.

2. How do patent expirations affect the supply of KLARON?
Post-patent expiry, multiple generic manufacturers enter the market, increasing supply options, reducing prices, and improving access. However, these entrants must navigate regulatory approvals and manufacturing capacity considerations.

3. What role do contract manufacturing organizations (CMOs) play in KLARON's supply chain?
CMOs provide specialized production services, facilitating scale-up, formulation development, and regional manufacturing, thereby enhancing supply chain flexibility and resilience.

4. Are regional regulatory agencies influencing KLARON suppliers?
Yes. Agencies like the FDA and EMA enforce strict quality standards that suppliers must meet, impacting licensing, manufacturing approvals, and market access.

5. What risks threaten the supply of KLARON, and how can they be mitigated?
Risks include manufacturing disruptions, geopolitical issues, regulatory delays, and quality failures. Mitigation involves diversifying suppliers, establishing regional manufacturing hubs, and maintaining strategic stockpiles.

Sources:

[1] Pharmaceutical Market Reports. "Global Supply Chain Dynamics for Biopharmaceuticals." 2022.
[2] U.S. Food and Drug Administration (FDA). "Approved Drug Products." 2023.
[3] European Medicines Agency (EMA). "Medicine Status and Manufacturing Approvals." 2022.
[4] Industry Publication: "Contract Manufacturing Trends in Pharmaceuticals." 2023.
[5] World Health Organization (WHO). "Essential Medicines and Supply Security." 2022.

Suppliers and packagers for klaron

klaron

Suppliers for the Pharmaceutical Drug: KLARON